RAMPART

End of Tremelimumab Treatment CRF - Form 07A
Version 1.0 25 June 2018

Patient Initials | Date of Birth (d d / m m m / y y y y) | Trial Number R

Visit Time Point ☐ Day 1 ☐ Week 2 ☐ Week 4 (please tick)

This CRF should be completed once the last cycle of Tremelimumab has been administered — i.e. at Week 4 for Tremelimumab or earlier if the patient stops treatment prematurely.

A. End of Tremelimumab Treatment — Arms C Patients Only

1 d d / m m m / y y y y **Date of last Tremelimumab infusion**

2 **Reason for ending trial treatment—***(Tick one only)*

- ☐ Protocol treatment completed
- ☐ Excessive toxicity
- ☐ Patient refusal
- ☐ Disease progression — *please complete a Progression CRF (Form 10)*
- ☐ New primary cancer — *please complete an SAE CRF (Form 13) and update the AE Log (Form 6)*
- ☐ Death — *please complete a Death CRF (Form 12)*
- ☐ Pregnancy — *please complete a Pregnancy Monitoring CRF (Form 14) and fax to the MRC CTU (0207 670 4653) within one working day*
- ☐ Intercurrent illness or change in patient's condition that justifies discontinuation of treatment in clinician's opinion
- ☐ Patient found to not be eligible for trial — *please discuss with the trial team (mrcctu.rampart@ucl.ac.uk)*
- ☐ Other, please specify:

.....

.....

3 **Did Tremelimumab treatment end due to an AE?**

- ☐ No
- ☐ Yes — *enter details on AE log (Form 06)*

4 **If treatment was ended due to an AE, state AE number.**

☐☐

ⓘ The **Adverse Events Log** must be completed up to **120 days** after the **Date of Last Infusion**.

Signature	Printed Name	Date Completed (d d / m m m / y y y y)

Please return a copy to RAMPART Trial, MRC Clinical Trials Unit at UCL, 90 High Holborn, 2nd Floor, London WC1V 6LJ

For office use only

Date form received at CTU dd / mmm / yyyy _____ Date form entered onto database dd / mmm / yyyy _____ Initials of data enterer ☐☐☐☐